The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from PR Newswire

Regeneron Announces Participation in J. P. Morgan Biotech: CEO/CFO Conference Call Series

Tuesday, May 11, 2010

Regeneron Announces Participation in J. P. Morgan Biotech: CEO/CFO Conference Call Series16:30 EDT Tuesday, May 11, 2010TARRYTOWN, N.Y., May 11 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will participate in the J. P. Morgan Biotech: CEO/CFO Conference Call Series at 10:00 a.m. Eastern Time on Friday, May 14, 2010. �Conference call details are as follows:Live conference call (US): �(888) 889-1309 Live conference call (Outside the US): �(773) 756-0161Passcode: �BIOTECHReplay (US): �(866) 501-0089Replay (Outside the US): �(203) 369-1817Passcode: �2597A recording of the call will be available for telephone replay until May 21, 2010.Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. �In addition to ARCALYST� (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration and central retinal vein occlusion), and certain cancers. �Additional therapeutic candidates are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer. �Additional information about Regeneron and recent news releases are available on Regeneron's web site at Information:Michael Aberman, M.D.Peter DworkinInvestor RelationsCorporate Communications914.345.7799 914.345.7640michael.aberman@regeneron.competer.dworkin@regeneron.comSOURCE Regeneron Pharmaceuticals, Inc.For further information: Michael Aberman, M.D., Investor Relations, +1-914-345-7799,, or Peter Dworkin, Corporate Communications, +1-914-345-7640,